Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity
- 16 December 2008
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 27 (7), 1040-1049
- https://doi.org/10.1016/j.vaccine.2008.11.099
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Antigen‐specific immunotherapy of cervical and ovarian cancerImmunological Reviews, 2008
- A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2Journal of Virology, 2007
- Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2Journal of Virology, 2007
- Association of cervical cancer with the presence of CD4+regulatory T cells specific for human papillomavirus antigensProceedings of the National Academy of Sciences, 2007
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- How will HPV vaccines affect cervical cancer?Nature Reviews Cancer, 2006
- Randomized Controlled Trial of an Adjuvanted Human Papillomavirus (HPV) Type 6 L2E7 Vaccine: Infection of External Anogenital Warts with Multiple HPV Types and Failure of Therapeutic VaccinationThe Journal of Infectious Diseases, 2005
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993